BRÈVE

sur SCHOTT Pharma AG & Co. KGaA

Leadership Transition at SCHOTT Pharma: Christian Mias Appointed CEO

SCHOTT Pharma has announced that Christian Mias will replace Andreas Reisse as CEO effective May 1, 2026. This transition follows Reisse's planned retirement in April 2026. The Supervisory Board has ensured a seamless leadership shift, with Reisse active in the transition period, maintaining continuity and stability. Christian Mias, an industrial engineer with extensive experience, has been with SCOTT for over 18 years. His roles have spanned continents and businesses, contributing to significant growth and profitability improvements.

Peter Goldschmidt, Chairman of the Supervisory Board, expressed confidence in Mias's ability to lead SCHOTT Pharma into its next phase of profitable expansion. Mias is joined by CFO Reinhard Mayer to continue advancing the company's status as a leader in pharmaceutical packaging. Mias acknowledges SCHOTT Pharma's reputation for innovation and aims to further build on this foundation.

Reisse, who has been instrumental in SCHOTT Pharma's growth and public listing, is confident in a prosperous future under Mias's leadership. The company is poised for continued success and innovation.

R. E.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SCHOTT Pharma AG & Co. KGaA